Abstract
Epidermal growth factor inhibition (EGFR) is emerging as an important treatment modality in several epithelial malignancies, including head and neck squamous cell carcinoma (HNSCC). Despite some notable successes, less than 20% of patients respond to EGFR inhibition due to intrinsic and acquired resistance. Since EGFR inhibition is already used for lung, colorectal, breast and pancreas cancers in addition to HNSCC, overcoming treatment resistance would have a major impact on outcome. When the mechanisms of intrinsic resistance are identified, including mutations in the EGFR receptor, alternative therapeutic approaches should be employed. Mechanisms of acquired resistance that may be amenable to pharmacological therapies include dysregulation of EGFR degradation, constitutive activation of overlapping signal transduction pathways, especially cMET/HER3, the PI3K/Akt resistance pathway, angiogenesis and epithelial to mesenchymal transition. COX-2 is another promising target for HNSCC and preclinical data suggest that COX-2 inhibitors can affect most of the described acquired EGFR resistance pathways. Several combined EGFR and COX-2 inhibition trials have been completed and demonstrate promise for HNSCC. Combinatorial strategies of combined inhibition of EGFR and acquired resistance pathways in combination with radiation or chemotherapy are warranted.
Keywords: EGFR, COX-2, head and neck cancer, erlotinib, celecoxib, radiation
Current Cancer Drug Targets
Title: Dual EGFR and COX-2 Inhibition as a Novel Approach to Targeting Head and Neck Squamous Cell Carcinoma
Volume: 9 Issue: 8
Author(s): J. Kao, A. T. Sikora and S. Fu
Affiliation:
Keywords: EGFR, COX-2, head and neck cancer, erlotinib, celecoxib, radiation
Abstract: Epidermal growth factor inhibition (EGFR) is emerging as an important treatment modality in several epithelial malignancies, including head and neck squamous cell carcinoma (HNSCC). Despite some notable successes, less than 20% of patients respond to EGFR inhibition due to intrinsic and acquired resistance. Since EGFR inhibition is already used for lung, colorectal, breast and pancreas cancers in addition to HNSCC, overcoming treatment resistance would have a major impact on outcome. When the mechanisms of intrinsic resistance are identified, including mutations in the EGFR receptor, alternative therapeutic approaches should be employed. Mechanisms of acquired resistance that may be amenable to pharmacological therapies include dysregulation of EGFR degradation, constitutive activation of overlapping signal transduction pathways, especially cMET/HER3, the PI3K/Akt resistance pathway, angiogenesis and epithelial to mesenchymal transition. COX-2 is another promising target for HNSCC and preclinical data suggest that COX-2 inhibitors can affect most of the described acquired EGFR resistance pathways. Several combined EGFR and COX-2 inhibition trials have been completed and demonstrate promise for HNSCC. Combinatorial strategies of combined inhibition of EGFR and acquired resistance pathways in combination with radiation or chemotherapy are warranted.
Export Options
About this article
Cite this article as:
Kao J., Sikora T. A. and Fu S., Dual EGFR and COX-2 Inhibition as a Novel Approach to Targeting Head and Neck Squamous Cell Carcinoma, Current Cancer Drug Targets 2009; 9 (8) . https://dx.doi.org/10.2174/156800909790192437
DOI https://dx.doi.org/10.2174/156800909790192437 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Innovative Cancer Drug Targets: A New Horizon in Oncology
Cancer remains one of the most challenging diseases, with its complexity and adaptability necessitating continuous research efforts into more effective and targeted therapeutic approaches. Recent years have witnessed significant progress in understanding the molecular and genetic basis of cancer, leading to the identification of novel drug targets. These include, but ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Interaction between Microbes and Host Intestinal Health: Modulation by Dietary Nutrients and Gut-Brain-Endocrine-Immune Axis
Current Protein & Peptide Science Characterization and Management of Cutaneous Side Effects Related to the Immunosuppressive Treatment in Solid Organ Recipients
Current Drug Targets MRI Combined with Magnetic Resonance Cholangiopancreatography for Diagnosis of Benign and Malignant Pancreatic Intraductal Papillary Mucinous Neoplasms
Current Medical Imaging Approaches to Targeting Cancer Stem Cells in Solid Tumors
Current Stem Cell Research & Therapy Development of Nitrile-Based Peptidic Inhibitors of Cysteine Cathepsins
Current Topics in Medicinal Chemistry Honokiol: A Novel Natural Agent for Cancer Prevention and Therapy
Current Molecular Medicine PAI-1 - A Potential Therapeutic Target in Cancer
Current Drug Targets PEDF as an Emerging Therapeutic Candidate for Osteosarcoma
Current Cancer Drug Targets Polyelectrolyte-graphene Nanocomposites for Biosensing Applications
Current Organic Chemistry Retrospective Observational Study to Evaluate Causality, Preventability and Severity of Adverse Drug Reaction Associated with Anticancer Drugs in a Tertiary Care Hospital in Northern India
Current Drug Safety In Vitro High Throughput Phage Display Selection of Ovarian Cancer Avid Phage Clones for Near-Infrared Optical Imaging
Combinatorial Chemistry & High Throughput Screening The Role of Diabetes in Molecular Pathogenesis of Cancer
Current Signal Transduction Therapy Berberine: A Fluorescent Alkaloid with a Variety of Applications from Medicine to Chemistry
Mini-Reviews in Organic Chemistry Biomedical Consequences of Alcohol Use Disorders in the HIV-Infected Host
Current HIV Research Histone Lysine-Specific Methyltransferases and Demethylases in Carcinogenesis: New Targets for Cancer Therapy and Prevention
Current Cancer Drug Targets Phosphorothioate Oligonucleotides: Effectiveness and Toxicity
Current Drug Targets Selective Inhibitors of Zinc-Dependent Histone Deacetylases. Therapeutic Targets Relevant to Cancer
Current Pharmaceutical Design The Potential Role of Soybean Bioactive Peptides in the Prevention and Cure of Carcinoma and Cardiovascular Disorder
Current Bioactive Compounds Inhibitors of the Ubiquitin-Proteasome System and the Cell Death Machinery: How Many Pathways are Activated?
Current Molecular Pharmacology MMP-9 Inhibitors in the Brain: Can Old Bullets Shoot New Targets?
Current Pharmaceutical Design